Cargando…
BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response
Major problems of current antidepressant pharmacotherapy are insufficient response rates and difficulties in response prediction. We recently provided preliminary evidence in a small study that patients with major depressive disorder (MDD) with a hypomethylation of the CpG-87 site of the promoter IV...
Autores principales: | Lieb, Klaus, Dreimüller, Nadine, Wagner, Stefanie, Schlicht, Konrad, Falter, Tanja, Neyazi, Alexandra, Müller-Engling, Linda, Bleich, Stefan, Tadić, André, Frieling, Helge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232909/ https://www.ncbi.nlm.nih.gov/pubmed/30459647 http://dx.doi.org/10.3389/fpsyt.2018.00511 |
Ejemplares similares
-
Dysregulated Methylation Patterns in Exon IV of the Brain-Derived Neurotrophic Factor (BDNF) Gene in Nicotine Dependence and Changes in BDNF Plasma Levels During Smoking Cessation
por: Abdelkhalek, Kerim, et al.
Publicado: (2022) -
BDNF exon IV promoter methylation and antidepressant action: a complex interplay
por: Pathak, Hansi, et al.
Publicado: (2022) -
BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression
por: Fonseca, Francina, et al.
Publicado: (2022) -
Antidepressive and BDNF effects of enriched environment treatment across ages in mice lacking BDNF expression through promoter IV
por: Jha, S, et al.
Publicado: (2016) -
Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
por: Losenkov, Innokentiy S., et al.
Publicado: (2020)